

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUYI INTERNATIONAL PHARMACEUTICAL COMPANY LIMITED

武夷國際藥業有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1889)

Date of Board Meeting

Reference is made to the announcement of Wuyi International Pharmaceutical Company (the “**Company**”) dated 31 March 2017 (the “**Announcement**”) in relation to the delay in publication of annual results announcement for the year ended 31 December 2016, postponement of board meeting and suspension of trading. Unless otherwise stated, capitalised terms used herein shall bear the same meanings as defined in the Announcement.

The Board hereby announces that a meeting of the Board will be held on Thursday, 13 April 2017, for the purposes of, among other matters, considering and approving the 2016 Audited Results, considering the recommendation of payment of a final dividend (if any) and other businesses.

SUSPENSION OF TRADING

At the request of the Company, trading in the shares of the Company on the Stock Exchange has been suspended with effect from 9:00 a.m. on 3 April 2017 and will remain suspended pending release of the Results Announcement.

By Order of the Board
Wuyi International Pharmaceutical Company Limited
Lin Ou Wen
Chairman and Chief Executive Officer

Hong Kong, 12 April 2017

As at the date of this announcement, the Board comprises 3 Executive Directors, namely, Mr. Lin Ou Wen (Chairman) and Mr. Chen Cheng Qing and Ms. Hung Hoi Lan, and 3 Independent Non-executive Directors, namely, Mr. Zhang Jie, Mr. Zhang Xue Wen and Mr. Wu Cheng Han.